plus_logo.png
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 14, 2024 16:15 ET | Plus Therapeutics Inc.
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
plus_logo.png
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
November 05, 2024 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
SloanePRLogo.jpg
Sloane & Company Expands its Healthcare Practice with the Appointment of Managing Director Leslie Wheeler
October 15, 2024 08:00 ET | Sloane & Company
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Sloane & Company, a strategic communications firm at the intersection of valuation and reputation, announces the appointment of Leslie Wheeler as a...
plus_logo.png
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
October 01, 2024 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
plus_logo.png
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
September 18, 2024 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting